Form 4 for DGX Quest Diagnostics
Accepted 2026-08-31 16:37:15 ET · period of report 2026-08-28 · accession 0001022079-26-000089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-31 16:37 | 2026-08-28 | DGX | PREVOZNIK MICHAEL E | SVP, GC | M - OptEx | $112.17 | +22.7K | 60.2K | +60% | +$2.54M |
| DMT | 2026-08-31 16:37 | 2026-08-28 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale+OE | $243.11 | -22.7K | 37.6K | -38% | -$5.51M |
| DT | 2026-08-31 16:37 | 2026-08-28 | DGX | PREVOZNIK MICHAEL E | SVP, GC | G - Gift | $0.00 | -1,000 | 36.6K | -3% | $0 |
| DT | 2026-08-31 16:37 | 2026-08-28 | DGX | PREVOZNIK MICHAEL E | SVP, GC | M - OptEx | $112.17 | -22.7K | 0 | -100% | -$2.54M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-28 | M | A | 22,677 | $112.17 | 60,234 | D | — | — | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. |
| 2 | Common | Common Stock | 2026-08-28 | S | D | 16,010 | $242.88 | 44,224 | D | — | — | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. (F2) This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2026-08-28 | S | D | 6,237 | $243.63 | 37,987 | D | — | — | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. (F3) This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2026-08-28 | S | D | 430 | $244.51 | 37,557 | D | — | — | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. (F4) This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2026-08-28 | G | D | 1,000 | $0.00 | 36,557 | D | — | — | (F5) On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. |
| 6 | Derivative | Non-Qualifed Stock Option (right to buy) | 2026-08-28 | M | D | 22,677 | $112.17 | 0 | D | $112.17 · — to 2030-02-18 | 22,677 Common Stock | (F1) This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. (F7) The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. |